According to the CSPC Innovation announcement, Jushi Biotech, a holding subsidiary of the company, received a down payment of 30 million US dollars from AstraZeneca on August 12, 2026. This payment is an amount agreed upon in the “Cooperation, Choice and Authorization Agreement” signed by the two parties on July 1, 2026. The two sides will carry out strategic cooperation in the field of novel low-interfering nucleic acid drug candidates to develop novel low-interfering molecule nucleic acid candidates for extra-hepatic delivery. The receipt of the down payment marks the smooth progress of cooperation, which is conducive to the company's overall strategic layout and accelerates the development of small nucleic acid pipelines.

According to the CSPC Innovation announcement, Jushi Biotech, a holding subsidiary of the company, received a down payment of 30 million US dollars from AstraZeneca on August 12, 2026. This payment is an amount agreed upon in the “Cooperation, Choice and Authorization Agreement” signed by the two parties on July 1, 2026. The two sides will carry out strategic cooperation in the field of novel low-interfering nucleic acid drug candidates to develop novel low-interfering molecule nucleic acid candidates for extra-hepatic delivery. The receipt of the down payment marks the smooth progress of cooperation, which is conducive to the company's overall strategic layout and accelerates the development of small nucleic acid pipelines.